US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 0.35 against a street estimate of 0.11 — a beat of 218.2%.
Analysts rate Eton Pharmaceuticals Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $71.50.
| Fund | Stake |
|---|---|
| Opaleye Management Inc | 10.01% |
| Nantahala Capital Management, LLC | 8.23% |
| EcoR1 Capital, LLC | 7.60% |
| BlackRock Inc | 6.63% |
| Vanguard Capital Management, LLC | 3.42% |
| Morgan Stanley - Brokerage Accounts | 2.69% |
| State Street Corp | 2.46% |
| Geode Capital Management, LLC | 2.28% |
| Document | Date |
|---|---|
| Company announcement · Q4 2026 BUSINESS & SEGMENT HIGHLIGHTS • Eton Pharmaceuticals announced ET-900, a new development program evaluating mecasermin injection for infantile and ep | 2026-11-02 |
| Material agreement · Q4 2026 HEADLINE NUMBERS • Eton Pharmaceuticals entered an agreement on October 13, 2026, to acquire exclusive U.S. commercialization rights for LIBERVANT® ( | 2026-10-14 |
| Company announcement · Q3 2026 HEADLINE NUMBERS • Eton Pharmaceuticals launched IMPAVIDO® (miltefosine) capsules on September 28, 2026. • The filing provides no revenue, earnings, | 2026-09-28 |
| Quarterly report · Q2 2026 ETON PHARMACEUTICALS, INC. – FORM 10-Q SUMMARY Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Net Income (6 months): $13,132 thousand ($0.41 pe | 2026-08-13 |
| Results announced · Q3 2026 ETON PHARMACEUTICALS Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 2026 product sales: $37.6 million, up 99% year-over-year from $18.9 million in | 2026-08-13 |
| Material agreement · Q3 2026 ETON PHARMACEUTICALS, INC. – 8-K SUMMARY HEADLINE NUMBERS • Upfront license fee: $3.0 million payable within 30 days to Auson Pharmaceuticals • Pote | 2026-08-05 |
| Board / officer change · Q3 2026 ETON PHARMACEUTICALS, INC. – 8-K SUMMARY HEADLINE NUMBERS • Company appointed Danka Radosavljevic as Chief Operating Officer effective July 31, 2026 | 2026-08-04 |
| Company announcement · Q3 2026 ETON PHARMACEUTICALS, INC. – DOCUMENT SUMMARY HEADLINE NUMBERS • Filing Date: July 29, 2026 • Company: Eton Pharmaceuticals, Inc. • Trading Symbol: | 2026-07-29 |
Readable in the app.
| Announcement | Date |
|---|---|
| Licensed patent rights and launched ET-900 development program for infantile and epileptic spasms Eton Pharmaceuticals announced ET-900, a development program testing mecasermin, the active ingredient in its existing INCRELEX product, for infantile and epileptic spasms. Eton licensed rel | 2026-11-02 |
| Exclusive U.S. licensing and supply agreement for LIBERVANT seizure rescue treatment Eton Pharmaceuticals agreed to exclusively commercialize LIBERVANT (diazepam buccal film) in the U.S. and its territories, under a separate supply arrangement with Aquestive Therapeutics. LI | 2026-10-14 |
| U.S. commercial availability of IMPAVIDO with exclusive commercialization rights Eton Pharmaceuticals announced the U.S. commercial launch of IMPAVIDO (miltefosine), a rare disease treatment for leishmaniasis. Eton acquired exclusive U.S. commercialization rights for the | 2026-09-28 |
| Raises full year 2026 revenue guidance to exceed $145 million Eton Pharmaceuticals reported exceptional Q2 2026 results with record revenue of $37.6 million, nearly doubling year-over-year (+99%). The company posted profitability with GAAP earnings per | 2026-08-13 |
| Acquires U.S. rights to late-stage infantile hemangioma product candidate ASN-001 Eton Pharmaceuticals acquired U.S. rights to ASN-001, a late-stage topical gel treatment for infantile hemangiomas (non-cancerous birthmarks). This is a strategic expansion of Eton's existin | 2026-08-05 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Eton Pharmaceuticals Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.